AR 231453
CAS No. 733750-99-7
AR 231453 ( —— )
产品货号. M21652 CAS No. 733750-99-7
AR 231453 是一种选择性口服 GPR119 激动剂,可以刺激 β 细胞复制并改善胰岛移植物功能。
纯度: >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| 规格 | 价格/人民币 | 库存 | 数量 |
| 2MG | ¥381 | 有现货 |
|
| 5MG | ¥510 | 有现货 |
|
| 10MG | ¥786 | 有现货 |
|
| 25MG | ¥1418 | 有现货 |
|
| 50MG | ¥2114 | 有现货 |
|
| 100MG | ¥3183 | 有现货 |
|
| 200MG | 获取报价 | 有现货 |
|
| 500MG | 获取报价 | 有现货 |
|
| 1G | 获取报价 | 有现货 |
|
生物学信息
-
产品名称AR 231453
-
注意事项本公司产品仅用于科研实验,不得用于人体或动物的临床与诊断
-
产品简述AR 231453 是一种选择性口服 GPR119 激动剂,可以刺激 β 细胞复制并改善胰岛移植物功能。
-
产品描述AR 231453 is a selective and orally available GPR119 agonistcan stimulate β-cell replication and improve islet graft function.
-
体外实验AR 231453 is inactive at all other GPCRs tested (more than 230, including all known pancreatic islet receptors), indicating that it is highly selective for GPR119.AR 231453 potently stimulats cAMP accumulation (EC50 = 4.7 nM) with a maximal efficacy similar to that seen with forskolin. AR 231453 significantly enhances insulin release in HIT-T15 cells, with an EC50 of 3.5 nM.AR 231453 also stimulates insulin release in isolated mouse islets at glucose concentrations ranging from 8-17 mM.
-
体内实验AR231453 (20 mg/kg, orally) markedly improves oral glucose tolerance in a dose-dependent fashion, with efficacy similar to maximally effective doses of the sulfonylurea glyburide. Animal Model:Mice.Dosage:20 mg/kg. Administration:Orally, once.Result:Improved glucose tolerance in mice.
-
同义词——
-
通路Cell Cycle/DNA Damage
-
靶点GPR
-
受体GPR119
-
研究领域——
-
适应症——
化学信息
-
CAS Number733750-99-7
-
分子量505.52
-
分子式C21H24FN7O5S
-
纯度>98% (HPLC)
-
溶解度DMSO:60 mg/mL (118.69 mM);H2O:60 mg/mL (118.69 mM; Need ultrasonic and warming)
-
SMILESCC(C)c1noc(n1)C1CCN(CC1)c1ncnc(Nc2ccc(cc2F)S(C)(=O)=O)c1[N+]([O-])=O
-
化学全称N-(2-fluoro-4-methanesulfonylphenyl)-(6-[4-(3-isopropyl-[124]oxadiazol-5-yl)-piperidin-1-yl]-5-nitropyrimidin-4-yl)amine
运输与储存
-
储存条件(-20℃)
-
运输条件With Ice Pack
-
稳定性≥ 2 years
参考文献
1.Chu ZL et al. A role for intestinal endocrine cell-expressed g protein-coupled receptor 119 in glycemic control by enhancing glucagon-like Peptide-1 and glucose-dependent insulinotropic Peptide release. Endocrinology. 2008 May;149(5):2038-47.
021-51111890
购物车()
sales@molnova.cn

